ClinicalTrials.gg
RecruitingNCT07930832Updated Nov 12, 2026

Study to Compare Traditional and Emerging Methods for Structural Variant Analysis in Prenatal, Postnatal, and Hematologic Samples

An observational study in Chromosome Aberrations, Aneuploidy and Chromosome Deletion, sponsored by 4bases Italia Srl. Recruiting at 2 sites in Italy. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionAneuploidyRegistry: Chromosome AberrationsReclassifiedWhy we changed it
Registry
Chromosome Aberrations — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aneuploidy
Why
  1. The study's listed conditions name Aneuploidy, a narrower term within Chromosome Aberrations.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by 4bases Italia Srl · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Aneuploidy with a site in Italy — 1 open to participants now, 1 under way, none of them phase 3. Aneuploidy · Italy.

Started
2026
the only one that year
Observational
7 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
4bases Italia Srl

Among the 11 studies in Aneuploidy with a site in Italy, this one is the only one that started in 2026, is one of 7 observational ones, and was the 11th registered.

Aneuploidy

75 studies on the registry are indexed under Aneuploidy; 12 are open to participants now.

Browse Aneuploidy studies →

Open to participants now

1 of the 11 studies in Aneuploidy with a site in Italy is open now.

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 10 Aneuploidy studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Aneuploidy with a site in Italy, or all of them as a file.
02

Study summary

The study goal is to evaluate an innovative technology, KaryoSolver, which enables molecular karyotype reconstruction, in comparison with reference conventional methods, in terms of:

Presence or absence of clinically detectable structural variants; Type of alteration (aneuploidies, deletions, duplications); Copy number present. KaryoSolver is a software system for reconstructing the molecular karyotype from low-coverage genomic sequencing data using long-read technology.

The expected performance of the device under study is its ability to detect and classify the main clinically detectable structural variants within included samples in a manner consistent with the reference comparators, using a standardizable workflow, competitive turnaround times, and adequate reproducibility.

Read the detailed description

In particular, the study contributes to demonstrating the following requirements:

  • scientific validity, through the correlation between Karyosolver and the aCGH/SNP array result used as a reference;
  • analytical performance, including accuracy, analytical sensitivity, analytical specificity, and reproducibility of the method, evaluated according to the criteria defined by ISO 5725;
  • clinical performance, through the evaluation of the test's ability to correctly identify copy number variations (CNVs) or regions of loss of heterozygosity (LOH/ROH) already reported in the samples selected for the study.
03

Conditions studied

  • Chromosome Aberrations
  • Aneuploidy
  • Chromosome Deletion
  • Chromosome Duplication
  • Abnormal Karyotype
  • Copy Number Variation

Browse trials for

Keywords

  • Molecular cytogenetics
  • Genome-wide chromosomal analysis
  • Oxford Nanopore sequencing
  • Diagnostic accuracy
  • Genetic Analysis Software
04

In context

Aneuploidy Reclassified

75 studies on the registry are indexed under Aneuploidy; 12 are open to participants now.

This study's planned enrollment of 200 is below the median of 290 across 40 observational studies indexed under Aneuploidy.

Browse Aneuploidy studies →

Lead sponsor

This is the only study on the registry with 4bases Italia Srl as lead sponsor.

Compared within Aneuploidy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chromosome Aberrations. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The biological samples are residual samples already available at the two participating clinical centers. The samples originate from diagnostic workups that have already been completed and were not collected specifically for this study. In particular, residual samples related to prenatal, postnatal constitutional, and oncohematological diagnostics may be used, in accordance with the criteria set forth in the protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prenatal, postnatal, and oncohematological samples.
  2. Availability of results obtained using at least one reference method.
  3. Valid for use in research.
  4. Sufficient quantity and quality of DNA for analysis.

Exclusion criteria

Exclusion Criteria:

  1. Absence of valid .
  2. Incomplete documentation of reference results.
  3. Insufficient or degraded DNA.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Overall diagnostic concordance between KaryoSolver and reference methods for the identification of clinically detectable structural variants.

    Time frame: through study completion, an average of 1 year

  2. Agreement on the presence/absence of clinically relevant chromosomal alterations between KaryoSolver and reference methods

    Time frame: through study completion, an average of 1 year

  3. Agreement by category of identified alteration (aneuploidies, deletions, duplications) between KaryoSolver and reference methods

    Time frame: through study completion, an average of 1 year

  4. Percentage of cases correctly classified by KaryoSolver compared to the reference comparator

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Intra-run reproducibility of KaryoSolver, assessed as the agreement of results obtained from replicates analyzed in the same session

    Time frame: through study completion, an average of 1 year

  2. Inter-run reproducibility of KaryoSolver, assessed as the agreement of results obtained from replicates analyzed in different sessions

    Time frame: through study completion, an average of 1 year

  3. Average analytical run time per sample with KaryoSolver compared to reference methods

    Time frame: through study completion, an average of 1 year

  4. Average total reporting time/turnaround time with KaryoSolver compared to reference methods.

    Time frame: through study completion, an average of 1 year

  5. Reduction in technical/interpretive workload, assessed in terms of man-hours or the number of manual tasks required

    Time frame: through study completion, an average of 1 year

  6. Average cost per sample analyzed with KaryoSolver compared to reference methods

    Time frame: through study completion, an average of 1 year

  7. Proportion of cases potentially eligible for faster diagnosis using KaryoSolver compared to the standard workflow

    Time frame: through study completion, an average of 1 year

08

Study locations

2 of 2 sites recruiting
  • SOD Diagnostica Genetica Azienda Osepdaliero-Universitaria Careggi
    Florence, 50134, Italy
    Recruiting
  • UOSD Genetica Medica e Genomica Azienda ULSS8 Berica
    Vicenza, 36100, Italy
    Recruiting
    • Daniela Zuccarello, Medical Doctor · Contactgenetica@aulss8.veneto.it · +39 0444-753360
    • Daniela Zuccarello, Medical Doctor · Principal investigator
09

References and documents

Individual participant data

Plan to share: No — IPD will not be shared because this is a non-interventional study which does not produce any health outcomes; it is, in fact, a performance study involving IVDs conducted solely for methodological research purposes, with no results being reported for diagnostic or therapeutic purposes.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Nov 12, 2026
StartActual
Sep 22, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07930832
Lead sponsor
4bases Italia Srl
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Sep 22, 2026
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Giulia Fugazza, Clinical Project Manager
Contact
info@4bases.ch
+41 (0) 91 224 70 81

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion